4.3. Dosage & Schedule

For adults, children and infants of age ≥6 months to ≤45 years: a single dose is given intramuscularly. For infants of age <6 months, a single dose is given intramuscularly. For children of age ≤6 years, a single dose is given intramuscularly.

4.4. Contraindications

• Hypersensitivity to any component or an agent similar in nature to the vaccine.

4.5. Special Warnings/Precautions

- Not recommended for patients with a history of non-relapsing meningitis.
- Not recommended for patients with a history of acute rheumatic fever.
- Not recommended for patients with a history of a previous severe reaction to the vaccine.

4.6. Interaction with other medicinal products/other forms of interaction

- No studies on the effect of the vaccine on the absorption, distribution, metabolism, or excretion of other medicinal products have been performed.

4.7. Pregnancy and Lactation

- In the event of fever or severe infection.
- Pregnant & lactating women.

4.8. Adverse Reactions

- Clinical laboratory tests are not required to ensure a safe and effective vaccine.
- Adverse reactions were monitored in clinical trials and reported in the package insert.
- The most common adverse events reported were local reactions (e.g., pain, redness, swelling) and systemic reactions (e.g., fever, headache).

5. Pharmacological Properties

- Typhoid fever is a common and serious bacterial disease caused by Salmonella typhi. The vaccine is indicated for active immunisation against salmonella typhi infection in 6 months to 54 years of age.

6.6. Special Precautions for Storage

- Do not store above 4°C.
- Do not freeze.
- Do not use after the expiration date printed on the label.
- Store in a cool, dry place.

6.7. Shelf Life

- The expiry date of the vaccine is indicated on the label and is valid for 36 months.

6.8. Special Precautions for Handling

- Do not use the vaccine after the expiration date printed on the label.
- Do not use the vaccine in children under the age of 6 months.
- Do not use the vaccine in patients with a history of severe reactions to the vaccine.

7.1. Presentation

- Typhoid Vi Conjugate Vaccine I.P.

8.1. Clinical PARTICULARS

- Typhoid Vi Conjugate Vaccine I.P.

9.1. Name and Description of the Medicinal Product

- Typhoid Vi Conjugate Vaccine I.P.

9.2. Qualitative and Quantitative Composition

- Each dose of 0.5 mL contains:
  - Purified Vi-Capsular Polysaccharide of S. typhi Ty2, 25 μg
  - Tetanus Toxoid carrier protein, 4 μg of PH₃ (Preservatives), 0.5 mg
  - Water for Injections (WFI), q.s. to 0.5 mL

9.3. Dosage & Schedule

- Typhoid Vi Conjugate Vaccine I.P.

9.4. Adverse Reactions

- The safety of Typhoid Vi Conjugate Vaccine I.P. has been evaluated in clinical trials and reported in the package insert.

9.5. Pharmacological Properties

- Typhoid Vi Conjugate Vaccine I.P.

9.6. Special Precautions for Storage

- Typhoid Vi Conjugate Vaccine I.P.

9.7. Shelf Life

- The expiry date of the vaccine is indicated on the label and is valid for 36 months.

9.8. Special Precautions for Handling

- Do not use the vaccine after the expiration date printed on the label.
- Do not use the vaccine in patients with a history of severe reactions to the vaccine.

9.9. Presentation

- Typhoid Vi Conjugate Vaccine I.P.

9.10. Name and Description of the Medicinal Product

- Typhoid Vi Conjugate Vaccine I.P.

9.11. Qualitative and Quantitative Composition

- Each dose of 0.5 mL contains:
  - Purified Vi-Capsular Polysaccharide of S. typhi Ty2, 25 μg
  - Tetanus Toxoid carrier protein, 4 μg of PH₃ (Preservatives), 0.5 mg
  - Water for Injections (WFI), q.s. to 0.5 mL

9.12. Dosage & Schedule

- Typhoid Vi Conjugate Vaccine I.P.

9.13. Adverse Reactions

- The safety of Typhoid Vi Conjugate Vaccine I.P. has been evaluated in clinical trials and reported in the package insert.